This FDA approval has now extended to anti‐PD‐1 antibodies (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, and dostarlimab), anti‐PD‐L1 antibodies (durvalumab, atezolizumab, and avelumab), and an anti‐LAG‐3 antibody (relatlimab) for the treatment of a variety of cancers.167. Here, PDCD1 is linked to cancer.